



Press Release 21th of September 2011

BioGaia signs agreement with the largest pharmaceutical company in the Philippines for its probiotic chewable tablets

Today BioGaia signed a distribution agreement with United Laboratories Incorporated, the largest pharmaceutical company in the Philippines, for its probiotic chewable tablets. The tablets will be sold under the BioGaia brand and the launch is planned to the first half of 2012.

United Laboratories has 6000 employees, the majority in the Philippines, but the company also has business in another 10 Asian countries. The agreement only concerns the Philippines, but BioGaia already has an agreement with United Laboratories' subsidiary in China.

BioGaia's Probiotic chewable tablets are sold in 44 countries, in 23 of these under the BioGaia brand.

– We are happy to partner with a science based company like BioGaia, says José María Ochave, Senior Vice President at United Laboratories Incorporated.

– The Philippines has a population of around 90 million people and a growing economy, which is why this market can be very interesting although the average level of income is comparatively low. United Laboratories has several sales forces that visit doctors, that is to say work in line with the successful business model that we use around the world, says Peter Rothschild, President at BioGaia.

For additional information please contact

Peter Rothschild, President, telephone: +46 8 555 293 00

Latest press releases from BioGaia

2011-08-18	BioGaia signs exclusive agreement with Fleet Laboratories in U.S.
2011-08-17	BioGaia AB interim report 1 January – 30 June 2011
2011-08-04	BioGaia signs agreement with the Moroccan pharmaceutical company Galenica SA for Morocco

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 21 Month 2011, 14:00 am CET.

BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium *Lactobacillus reuteri* (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm.
www.biogaia.com